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Summary
 
The efficacy of triple drug therapy for HIV-1 infection encourages its early use to prevent
damage to the immune system. We monitored the effects of such therapy on 12 patients with
14–75-mo histories of minimal disease, i.e., CD4
 
1
 
 counts constantly 
 
.
 
500/
 
m
 
l and little or no
lymph node enlargement. In this way, we could first determine the extent of viral replication
and immunoarchitectural changes in unenlarged nodes early in disease, and second follow the
response to triple therapy in plasma and lymphoid tissue in tandem. As is known for lymph
nodes with more advanced disease, the germinal centers showed productively infected T cells,
i.e., CD4
 
1
 
CD1a
 
2
 
CD68
 
2
 
 cells labeling intensely for HIV-1 RNA after in situ hybridization.
The unenlarged nodes also showed extensive HIV-1 RNA retention on a well-preserved, fol-
licular dendritic cell (FDC) network, and the follicles were abnormal. There were numerous
CD8
 
1
 
 cells, many expressing TIA-1 granule antigen. Also, in contrast to normal follicles,
CD4
 
1
 
 T cell proliferation was active, with marked increases in the number of cycling, Ki-
67
 
1
 
CD4
 
1
 
CD45R0
 
1
 
 cells. After 28 d and 3 mo of therapy, productively infected T cells de-
creased dramatically and often were not apparent. The labeling of the FDC network for viral
RNA also decreased, but not for gag protein. We conclude that HIV-1 replicates and accumu-
lates in lymphoid organs before damage of the immune system, that at this stage of disease de
novo production of T cells occurs in the lymphoid tissue, and that the infection is sensitive to
triple drug therapy in both plasma and lymph nodes.
 
R
 
ecent developments in antiretroviral therapy have led
to substantial advances in the management of patients
infected with human immunodeficiency virus type 1
(HIV-1). The combination of two nucleoside analogues,
e.g., zidovudine (AZT), didanosine (ddl) or zalcitabine
(ddC), and an HIV-1 protease inhibitor (triple drug ther-
apy) typically yields a dramatic reduction of HIV-1 RNA
in the plasma and a significant increase in CD4
 
1
 
 T cells in
the peripheral blood (1, 2). It is now important to assess
therapeutic responses in the tissues and not just viral loads
and CD4
 
1
 
 lymphocytes in the blood. It is well established
that HIV-1 particles, gag proteins, and viral RNA are re-
tained on the surface of follicular dendritic cells (FDCs)
 
1
 
 in
germinal centers (GCs) (for review see reference 3). By in
situ hybridization with HIV-1 RNA probes, productively
infected cells are also numerous, particularly in the GCs (4–
11). Treatment strategies should therefore reduce these
large depots of viral RNA and infected cells in the lym-
phoid tissue. Indeed, Cavert et al. have recently docu-
 
1
 
Abbreviations used in this paper:
 
 APAAP, alkaline phosphatase anti–alkaline
phosphatase; ELT, extrafollicular lymphoid tissue; FDC, follicular den-
dritic cell; GC, germinal center; PGL, persistent generalized lymphade-
nopathy; SSC, standard saline citrate.
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mented a marked decrease in viral RNA in tonsil biopsies
from patients with advanced disease who were treated with
combination antiretroviral drugs (12). 
A favorable therapeutic response also should restore the
architecture of the lymphoid tissue that is severely altered
during HIV-1 infection (for review see reference 13). Fol-
licular hyperplasia usually is observed in patients with per-
sistent generalized lymphadenopathy (PGL). This is associ-
ated with varying degrees of FDC damage and a marked
elevation of CD8
 
1
 
 lymphocytes in both the T-dependent
zone and the GCs, the latter being an unusual site for
CD8
 
1
 
 T cells. However, there has been little work on
lymph node architecture and viral burden in patients with
high CD4
 
1
 
 T cell counts and no PGL. 
The use of combination therapy early in disease holds
the potential of preventing virus-induced damage to the
immune system. Therefore, we initiated triple drug therapy
in infected seropositive asymptomatic patients with CD4
 
1
 
counts constantly 
 
.
 
500/mm
 
3
 
. Most of the individuals
lacked lymphadenopathy. The goal of this study, therefore,
was twofold. First we sought information on histology and
viral replication in nonenlarged lymph nodes, given that
earlier data was obtained from patients with PGL. Second,
we wanted to assess the effects of triple drug therapy on
lymph node HIV-1 RNA and p24, as well as immunoar-
chitectural restoration of lymphoid tissue.
 
Materials and Methods
 
Patients. 
 
12 volunteers were enrolled. Eligibility criteria
were: laboratory documentation of HIV-1 infection, CD4
 
1
 
 T
cell counts constantly 
 
.
 
500 cells/
 
m
 
l, no history of AIDS-defining
events, no prior antiretroviral therapy, and 
 
.
 
18 yr old. All patients
gave written consent to participate. The study was approved by
the local ethics committee (Arztekammer, Hamburg, Germany).
Important clinical data are summarized on Table 1. There were
two groups: eight patients who had no evidence of lymphade-
nopathy (group A) and four who had at least two peripheral lymph
nodes 
 
.
 
3 cm (group B). Biopsies of axillary lymph nodes (group
A) or an enlarged node (group B) were done under local anesthe-
sia within 7 d before beginning therapy. All patients received 250
mg zidovudine t.i.d., 0.75 mg zalcitabine t.i.d, and 2,400 mg san-
quinavir t.i.d. Plasma viremia and CD4
 
1
 
 T cell counts were de-
termined at days 0, 3, 7, 10, and 14, and weekly thereafter. The
second lymph node biopsy was performed either 28 d (group A)
or 3 mo (group B and patient No. 8 from group A) of treatment. 
 
Light microscopy.
 
Tissues were fixed in 4% neutral-buffered
formalin overnight, embedded in paraffin, and stained with he-
matoxylin and eosin, Giemsa, or Gomori silver impregnation for
routine histology. Portions of lymph nodes were embedded in
tissue freezing medium (Leica Instruments, Nussloch, Germany),
snap frozen in liquid nitrogen, and stored at 
 
2
 
70
 
8
 
C until use. As
controls, 10 lymph nodes with follicular hyperplasia not related to
HIV infection were selected from our files. 
 
Immunohistochemistry. 
 
Dewaxed paraffin sections were placed
in a domestic pressure cooker containing 0.01 M buffered sodium
citrate solution (pH 6), boiled for 2 min, and chilled to room
temperature (14). Cryostat sections were fixed in 2% paraformal-
dehyde for 10 min. The sections were incubated with the pri-
mary antibodies (Table 2) according to the manufacturers’ in-
structions. Binding of antibodies was visualized by the alkaline
phosphatase anti–alkaline phosphatase (APAAP) technique using
New Fuchsin as chromogen. The sections were either counter-
stained with hematoxylin and mounted, or dehydrated through
graded ethanols and subjected to in situ hybridization to detect
HIV RNA.
 
Immunohistochemical Double Labeling. 
 
Proliferating CD4
 
1
 
 T
cells or CD8
 
1
 
 lymphocytes, and the TIA-1
 
1
 
 CD8
 
1
 
 T cell subset,
were detected on paraffin sections. After heat-mediated, antigen
retrieval in a pressure cooker, the sections were incubated with
anti-CD4 or -CD8 mAbs at 4
 
8
 
C overnight. Binding of antibodies
was detected either with biotin-avidin peroxidase or with
APAAP using New Fuchsin as red chromogen. The sections
were then heat treated again for 5 min and incubated either with
antibody MIB-1 to the proliferation antigen Ki-67 (15), or with
 
Table 1.
 
Patient Characteristics at Baseline
 
Patient
No. Gender Age HIV
 
1
 
CD4
 
1
 
CD4/CD8
ratio
Virus load
RNA PGL
Second
bx
 
mo cells/
 
m
 
l eq/ml
 
1 Male 51 75 540 0.24 300,000 No 28 d
2 Male 27 39 580 0.65 49,000 No 28  d
3 Male 32 60 510 0.75 15,000 No 28 d
4 Male 27 28 610 0.86 10,000 No 28 d
5 Female 30 67 1,350 0.68 6,500 No 28 d
6 Male 39 69 560 0.58 6,000 No 28 d
7 Female 46 43 570 0.80
 
,
 
500 No 28 d
8 Male 27 28 670 0.86
 
,
 
500 No 3 mo
9 Male 56 14 380 0.18 48,000 Yes 3 mo
10 Male 27 15 570 0.50 37,500 Yes 3 mo
11 Male 35 52 560 0.50 31,000 Yes 3 mo
12 Male 39 75 560 0.26 9,200 Yes 3 mo 
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the TIA-1 mAb that reacts with killer cell granules (16) overnight
at 4
 
8
 
C. The second antibody was visualized with APAAP and
Fast Blue salt.
 
Immunofluorescence Studies. 
 
The association of HIV p24 with
FDCs and T cells was analyzed on frozen sections by two-color
immunofluorescence beginning with FITC-antibodies to CD23
(FDCs), CD4, or CD8. This was followed with an unlabeled an-
tibody to p24, CD25, or CD45R0, and TRITC-goat anti–
mouse Ig.
 
Detection of HIV RNA in Lymph Nodes.
 
An 
 
35
 
S-labeled, sin-
gle-stranded, antisense RNA probe (Lofstrand Labs., Gaithers-
burg, MD) was used. The probe contained 1.4–2.7-kb fragments
collectively representing 
 
z
 
90% of the HIV-1 genome (8). The
hybridization was done on paraffin and frozen sections, the latter
being fixed in 4% paraformaldehyde for 20 min before hybridiza-
tion. To increase the diffusion of the probe, paraffin sections were
treated either with proteinase K (0.01 mg/ml) for 8 min at room
temperature or were placed in a domestic pressure cooker con-
taining citrate buffer and heated for 5 min. The pairs of sections
were processed at the same time. The sections were placed in a
cocktail (50% formamide, 0.5 M NaCl, 10 mM Tris HCl, pH
7.4, 1 mM EDTA, 0.02% Ficoll-polyvinylpyrrolidone-BSA, and
7 mg of tRNA/ml) and prehybridized for 2 h at 45
 
8
 
C. The sec-
tions were covered with a hybridization mixture (prehybridiza-
tion cocktail, 10% dextran sulfate, and 2 
 
3 
 
10
 
6
 
 dpm of probe/ml)
and incubated in a 45
 
8
 
C moist chamber overnight. The sections
were washed for 15 min with three changes, each in 50% forma-
mide: 50% 2
 
3 
 
standard saline citrate (SSC), 2
 
3
 
 SSC–0.1% Tri-
ton, and finally 0.1
 
3 
 
SSC. Sections were digested with RNase
(Boehringer Mannheim GmbH, Mannheim, Germany) at 37
 
8
 
C
for 40 min, washed again in 2
 
3 
 
SSC, and dehydrated in 0.3 M
ammonium acetate with 70–90% ethanol. The slides were dipped
into emulsion (NTB2; Kodak, Rochester, NY). After 7 d of ex-
posure at 4
 
8
 
C, the slides were developed in developer (D19;
Kodak), fixed, counterstained with hemalaun, and mounted. As a
positive control, cytospin preparations of H9 cells infected with
HIV-1 were hybridized with the same probe. As a negative con-
trol, sections were hybridized with a radiolabeled sense-strand
probe. The sections were examined with a microscope (Axio-
phot; Carl Zeiss Inc., Jena, Germany) equipped with epilumines-
cent illumination. Cells were considered positive for viral gene
expression if the grain count was more than six times the highest
background.
 
Semiquantitative Image Analysis of HIV RNA. 
 
To examine the
extent and density of diffuse HIV RNA signals in the GCs, we
used a microscope (Axioskop; Carl Zeiss Inc.) equipped with
Plan Neofluar for transmitted and incident light, a 3CD color
camera, and a PC-based image analysis system (KS 400; Kontron,
Esching, Germany). In the first step, the transmission light image
of the lymph node sections was digitalized and stored. An inci-
dent light image showing the reflectance of the silver grains was
then obtained. Subsequently, these two images were superim-
posed. The area occupied by silver grains (RNA) was expressed as
a percentage value of total GC area.
 
Semiquantitative Image Analysis of Proliferating CD4 or CD8 T
Cells. 
 
Using a 
 
3
 
40 objective, regions of GCs and T zones were
 
Table 2.
 
Antibodies Used in This Study
 
Antibody CD
(clone)
Main specificities
in lymphoid tissue
Dilution
Source Paraffin Frozen
CD1a (010) Subset of DC and T Undiluted ND Immunotech
 
*
 
CD1a (Leu 6) Subset of DC and T ND 1:10 Becton Dickinson
CD4 (NCL-CD4-1F8) T helper, DC, mac 1:40 1:50 Novocastra
CD8 (C8/144B) T cytotoxic 1:10 1:40 Dakopatts
CD20 (L26) B cells 1:50 1:50 Dakopatts
CD23 Fc
 
e
 
 receptor II 1:50 1:100 Dakopatts
CD57 (Leu 7) NK subset, T subset 1:10 1:10 Becton Dickinson
CD68 (KP1) macrophages, some DCs 1:10 1:50 Dakopatts
CD45R0 (UCHL-1) activated, memory cells 1:100 1:200 Dakopatts
CD25
 
b
 
 chain of IL-2 receptor ND 1:5 Becton Dickinson
anti-p24 p24 protein of HIV-1 1:5 1:10 Dakopatts
MIB-1 Ki-67 cell cycle 1:10 1:20 Dianova
Ki-M4p FDC 1:50 1:100 M. Parwaresch
 
‡
 
TIA-1 15-kD protein in 1:500 ND Coulter
cytotoxic cells
p55 EBV induced; DC 1:5 1:5 E. Langhoff
S-100 (15E2E2) Subset of DCs 1:100 ND Boehringer
Mannheim
 
*
 
Immunotech, Marseille, France; Becton Dickinson, Mountain View, CA; Novocastra, Newcastle upon Tyne, UK; Dakopatts, Copenhagen, Den-
mark; Dianova, Hamburg, Germany; Coulter Corp., Krefeld, Germany; Boehringer Mannheim GmbH, Mannheim, Germany.
 
‡
 
M. Parwaresch, University of Kiel, Kiel, Germany; E. Langhoff, University of Hershey, Hershey, PA.
DC, dendritic cell.  
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marked on the monitor. Total CD4
 
1
 
 or CD8
 
1
 
 cells, and double
positive cells (CD4/Ki-67 or CD8/Ki-67), were counted. Ten
fields of GCs and T zones were counted on each slide. The per-
centage of a T cell subset expressing MIB-1 was calculated in the
designated areas.
 
Assay for Detection of HIV-1 RNA in Plasma. 
 
Plasma aliquots
were stored at 
 
2
 
70
 
8
 
C. HIV-1 RNA was measured using PCR
(Amplicor Monitor HIV-1; Hoffmann-La Roche, Basel, Switzer-
land) according to the manufacturer’s instructions (17). The limit
of detection of this assay is 200 RNA copies/ml. When levels be-
low this cutoff were found, an ultrasensitive version (20 copies/ml)
of this assay was performed.
 
Results
 
Technical Considerations of HIV RNA Detection. 
 
To al-
low for the penetration of probes into paraffin sections, tis-
sue permeabilization is usually necessary. Current protocols
recommend pretreatment with HCl and digitonin and/or
proteinase K (8, 18). However, we find that these agents
damage the morphology, making the evaluation of patho-
logic changes difficult. Furthermore, recently available an-
tibodies that detect CD4
 
1
 
 or CD8
 
1
 
 T cells in paraffin sec-
tions (Table 2) do not react if the sections are treated with
proteolytic enzymes but instead require superheating be-
fore immunostaining. Since high temperature also dena-
tures RNA, yielding unfolded linear forms to which probes
hybridize efficiently, we reasoned that boiling of tissue sec-
tions might intensify both RNA hybridization and immu-
nostaining with new mAbs while preserving morphology.
In pilot experiments, sections were boiled in a domestic
pressure cooker for 5 min (14). Companion sections were
pretreated with 0.2 N HCl for 30 min followed by protein-
ase K in various concentrations (5–20 
 
m
 
g/ml) at 37
 
8
 
C or at
room temperature for 8–15 min, and hybridized according
to published protocols (8, 18). Sections were exposed at
4
 
8
 
C for 1, 3, 4, 5, 7, and 10 d to optimize autoradiographic
signals. 
Treatment of sections with high temperature substan-
tially increased the number (50–70%) and grain counts of
actively infected or “hot” cells (cells labeling heavily with
antisense RNA probe) over prior reports (3–12, 18, 19;
Fig. 1, 
 
right
 
, 
 
arrows
 
). However, protein digestion facilitated
the access of the probe to FDC-bound HIV that is com-
plexed with antibodies, giving increased diffuse FDC label-
ing (8, 20; Fig. 1, 
 
left
 
, 
 
arrow
 
). We confirmed the findings of
Cavert et al. (12) that longer autoradiographic exposure
times increased the sensitivity of in situ hybridization in
both approaches. For example, a 1-d exposure (recom-
mended to quantitate FDC-bound HIV RNA; reference
18) gave low grain counts and low frequencies of produc-
tively infected cells, but exposure times of 5–7 d increased
the numbers of hot profiles and FDC-bound HIV RNA.
Further lengthening of exposure times did not increase sen-
sitivity and led to a reduction of signal/noise ratio. 
Because high temperature treatment provided for (
 
a
 
) im-
munohistochemical detection of important antigens, (
 
b
 
) ef-
Figure 1. Methodological aspects of HIV-1 RNA detection. Adjacent lymph node sections were treated by boiling in a pressure cooker (right) or with
proteinase K (left), and then hybridized with radiolabeled antisense RNA probes. The autoradiograms were photographed under bright field microscopy.
The boiled sections contained more numerous, discretely labeled, productively infected or hot cells (arrows, right), and tissue preservation was better. Pro-
teinase K–treated sections, in contrast, exhibited a more heavily labeled FDC network of RNA (arrow, left).953 Racz et al.
ficient RNA hybridization signals with low background
noise, and (c) well-preserved morphology, we used this
method to monitor the structure of lymphoid organs and
the numbers of HIV-1–producing cells. Digestion with
proteinase K of additional sections was used to analyze
FDC-bound HIV RNA. The high density of hybridization
signals over single cells and the FDC network did not per-
mit counting of the silver grains, so HIV-1 copy numbers
were not calculated in the manner that was described pre-
viously (12, 18). Instead, therapy-induced changes were
monitored semiquantitatively in terms of the area of GCs
occupied by diffusely distributed silver grains and expressed
as the percentage of total GC area. HIV RNA1 cells were
counted over the entire section, and their localizations
were noted. Since labeled cells localized preferentially to B
cell follicles (Fig. 1), we used the term extrafollicular lym-
phoid tissue (ELT) for all nonfollicular regions, omitting
further distinction of T-dependent zones, interfollicular ar-
eas, medulla, and sinuses. 
Detection of HIV RNA in Lymph Nodes at the Baseline.
Even though most of the lymph nodes were not enlarged,
we still observed viral RNA in all. As in enlarged nodes (3–
12, 18, 19), there were two patterns of hybridization sig-
nals: diffuse labeling over the FDC network in the light
zones of GCs, and strong localized labeling of single cells,
usually in GCs and the mantle zone (Fig. 1). Plasma RNA
levels correlated directly with the frequency of hot HIV-
infected cells in the lymph nodes (Fig. 2). The area of GCs
occupied with FDC-associated RNA varied about twofold
over the range of plasma RNA levels in our patient cohort
(see Table 4).
Two patients had very low plasma RNA levels of ,500
copies/ml before treatment. Patient No. 8 showed only a
few infected cells in the ELT but no diffuse labeling over
FDCs, which were present. Patient No. 7 had a diffuse hy-
bridization signal over 15–30% of the GCs, with produc-
tively infected cells mainly in ELT (up to 10 cells/cutting
level) and rarely in GCs (up to 3/cutting level). We con-
clude that normal-sized nodes from patients with CD4
counts of .500/ml and low levels of plasma RNA show
clear productively infected cells and viral RNA accumulation.
Light Microscopy and Lymphocyte Subsets in the Lymph
Nodes before Therapy.  The classical microanatomy of the
lymph nodes, i.e., the cortex, the paracortex, the medulla,
and the sinuses were well preserved and showed histologic
alterations commonly seen in viral lymphadenitis. The si-
nus system was slightly dilated and contained many lym-
phocytes, macrophages, and not seldomly, neutrophils. The
T-dependent zones, identified by the presence of high en-
dothelial venules and interdigitating dendritic cells (S-1001
and p551), were well developed with increased high en-
dothelial venules and many CD31 T and CD201 B blasts.
Increased numbers of plasma cells and macrophages were
also seen in the interfollicular regions. 
The histology of the GC differed in the two groups.
Only the enlarged lymph nodes from group B patients had
the previously described, HIV-1–associated, follicular hy-
perplasia. The follicles, located both in the cortex and more
diffusely, were enlarged (.700-mm diam) and irregularly
shaped, with serrated or protruding margins, sometimes be-
coming confluent. Attenuation of the mantle zone was evi-
dent in some follicles. The GCs showed clear zonation.
The light zone had centrocytes, CD41 T cells, and some
plasma cells. The dark zone contained many centroblasts (B
blasts) and tingible body macrophages. In group A patients
with unenlarged nodes, follicular size was normal, 300–450
mm diam (21). The follicles were usually round and the
GCs showed zonation with only slightly extended dark
zones. As in follicular hyperplasia, the follicles had a cortical
and diffuse distribution occupying 17–24% of the lymph
node cross-sectional area. 
The numbers of CD41 T cells both in the follicles and
T-dependent zones were in the same range as that seen in
non-HIV–infected, control lymph nodes (Fig. 3 a; Table
3). As in follicular hyperplasia not attributed to HIV infec-
tion, .95% of the CD41 cells in the GCs were CD45RO1
and z40–60% also expressed CD57. The proportion of
CD41CD45RO1 cells (41–63%) in the T-dependent
zones did not differ significantly from control nodes. The
number of CD41CD251 activated T cells showed a wide
range of variation (1.4–15.1%) within the same section, but
in HIV-infected patients more CD41 lymphocytes in the
GCs expressed this activation marker than in the controls.
As reported in HIV-12 lymph nodes (22, 23), no CD251
cells were found among the intrafollicular, CD571CD41
cells.
Abnormalities in the Follicles of Unenlarged HIV-1–infected
Lymph Nodes.  In HIV-1 infection, continuous virus rep-
lication results in a loss of CD41 lymphocytes with z109
CD41 T cells being destroyed each day (24). In our pa-
tients, the levels of CD41 T cells were in the normal range,
both in the circulation and in the lymph node, in spite of
the fact that infection was acquired 1–6 yr earlier. There-
fore, we determined the growth fraction of the CD41 cells
to see if peripheral T cell numbers might be maintained in
the nodes. In agreement with published data (25), we found
Figure 2. Direct relationship between the number of productively in-
fected cells in lymph node sections and the level of plasma RNA (correla-
tion coefficient: 0.65). The data are mean numbers of hot GC cells per
lymph node section.954 HIV-1 Infection and T Cell Growth in Unenlarged Nymph Nodes
Figure 3. Architecture and immunolabeling of infected lymph nodes. (a) CD41 T cells (red) were abundant in the T cell area (T), but were also found
in the B cell follicle, as is typical of normal lymph nodes. (b) However, in HIV-1 infection, CD41 T cells (red) showed an increase in the extent of label-
ing for Ki-67 (blue; arrows, double positive cells). (c) In HIV-1 infection, CD81 T cells (brown, arrow) were abundant in GCs (B) that were full of Ki-671
B blasts (blue). (d) The FDC network (arrows) was visualized with the Ki-Mp4 monoclonal antibody.
Figure 4. Effect of triple drug therapy on lymph node HIV-1 RNA. (a and b) The in situ hybridization signal for viral RNA in the FDC network is
shown by reflected light (turquoise, arrow) before (a) and after (b) 28 d of therapy. (c and d) The immunolabeling signal for viral p24 or gag protein in the
FDC network is shown (red) together with the in situ hybridization for viral RNA (turquoise). Before therapy (c), the red p24 (arrow) was obscured by the
silver grains over viral RNA. After therapy (d), p24 persisted and was readily visible because the viral RNA signal was so weak.955 Racz et al.
that intrafollicular T cells in noninfected patients usually
were not proliferating, i.e., 0–3% expressed the Ki-67 cell
cycle antigen (Table 3). This contrasted to our group A and
B lymph nodes in which 8–31% of the CD41 cells in GCs
expressed Ki-67 (Fig. 3 b; Table 3). In the T-dependent
zone, the differences in proliferation index between con-
trols and infected lymph nodes were less pronounced (0.9–
5.4 versus 0.4–4.6% in the control lymph nodes). In con-
trast to CD41 lymphocytes, CD81 T cells proliferated
mainly in the ELT. In the T-dependent zone, 2.7–7.0% of
the CD81 cells were cycling, but in the GC, only 0.2–
0.8% of the CD81 cells were Ki-671.
In all infected patients, the numbers of CD81 lympho-
cytes were markedly elevated both in the follicles and the
ELT (Fig. 3 c). This led to markedly decreased CD4/CD8
ratios in the T-dependent zone (1.3 versus 3.7 in unin-
fected controls) and in the GC (1.6 versus 19.8 in controls).
Within GCs, CD81 cells were almost uniformly CD45RO1
(.95%), whereas in the T zone, 57–72% of CD81 cells be-
longed to this memory subtype. Up to two thirds of CD81
cells in the T-dependent zone, and nearly all CD81 T cells
in the GCs, contained TIA-11 cytotoxic granules. Thus, in
follicles and in T zones, the proportion of CD81 T cell
subsets was similar to that seen in persistent generalized
lymphadenopathy (26, 27)
The Ki-M4p mAb to FDCs showed that the FDC net-
work was largely confined to the light zone of the infected
GCs (Fig. 3 d). Even though CD81TIA1 T cells had in-
vaded the follicles, no evidence of significant damage to the
FDC network was apparent. The CD23 antigen on FDC
was upregulated. The band of CD231 FDCs was expanded
into the basal light zone and, in patients with plasma vire-
mia .50,000 copies/ml, into the neighboring regions of
the dark zone. Double labeling revealed that immune com-
plexes of HIV-1 p24 antigen were bound only on the
CD231 portion of the FDC network.
Phenotype of HIV RNA1 Cells.  In situ hybridization
and immunohistochemistry together revealed that CD41
lymphocytes expressed viral RNA both in the GCs and
ELT (not shown). Exclusively CD45RO1 memory type,
CD41 T cells replicated HIV-1. Viral RNA was not de-
tected in the CD571 subset that resides in the GCs. Only a
minority of cells with HIV gene transcripts expressed
CD25. We were not able to detect CD681 macrophages or
CD1a1 dendritic cells with viral RNA. The diffuse RNA
labeling was found on the CD231-activated part of the
FDC network. 
Viral RNA and Immunohistologic Changes in Lymph Nodes
of Treated Patients. Triple drug therapy markedly reduced
HIV-1 RNA in the plasma of all patients, and in the lymph
nodes of all but one at day 28 (Table 3). Three patients
(baseline viral load of 300,000, 6,500, and 500 copies/ml)
had no detectable productively infected cells. Thus, a major
reduction in virus-producing cells was not dependent on
the virus load in the plasma or the number of HIV RNA1
cells in lymph nodes at the baseline. In all other patients
treated for 28 d, a few HIV-1 RNA1 cells could still be de-
tected in the GCs (up to three per section) and in the ELT
(up to four per section). Phenotyping of the residual hot
cells after treatment revealed no change to a nonlymphoid
phenotype. The extent (Fig. 4, a and b; Table 4) and den-
sity of diffuse FDC labeling in GCs also showed a marked
reduction after 28 d of treatment.
In patients treated for 3 mo, we could not detect hot
productively infected cells in either paraffin or cryostat sec-
tions. FDC-bound HIV RNA remained decreased in all
cases. Surprisingly, GCs did not react uniformly. 34–78%
of GCs contained no hybridization signals at 20 cutting
Table 3. Percentage of T Cell Subsets in Lymph Nodes of HIV1 Patients and HIV2 Controls
T cell
subsets
Controls, HIV2 Group A, HIV1 Group B, HIV1
GC T zone GC T zone GC T zone
CD41Ki-671 1.4 6 0.4  2.6 6 0.6  19 6 2.0  3.9 6 0.5  18 6 1.7  3.4 6 0.7 
(0–3) (0.4–4.6) (8–31) (0.9–5.4) (9.8–28) (1.3–5.0)
CD81Ki-671 ND 2.9 6 0.3  0.6 6 0.1  5.7 6 0.4  1.0 6 0.2  5.1 6 1.0 
(1.5–3.9) (0.2–0.8) (2.7–7.0) (0.4–1.9) (2.0–6.0)
CD41CD45R01 .95 43 6 6.5 .95 50 6 3.7 .95 43 6 2.8
(38–51) (41–63) (34–57)
CD81CD45R01 ND 25 6 2.2 .95 65 6 5.3 .95 69.0 6 3.3
(19–32) (57–72) (60.0–72.8)
CD81TIA-11 ND 49 6 5.0 .95 73 6 3.5 .95 75 6 1.4
(36–58) (61–79) (60–81)
CD4/CD8 ratio 20 3.7 1.6 1.3 1.8 1.5
(14–31) (2.5–5.8) (1.0–2.4) (0.9–2.0) (1.0–2.7) (1.0–2.5)
*Values are 6 SE based on 10 fields of T-dependent zone/lymph node and on 8 GCs/lymph node. Range is shown in parenthesis.
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levels, but in some follicles, up to 12.5% of the GC was oc-
cupied by HIV RNA with a low intensity of hybridization.
Unexpectedly, FDC-bound HIV-1 p24 was not overtly re-
duced after triple drug treatment (Fig. 4, c and d). Immuno-
histochemical and histologic changes at the baseline, e.g.,
follicular hyperplasia, increased CD81 cells, high T cell
proliferation rates, were not changed by therapy. 
Discussion
Active HIV-1 Accumulation in Unenlarged Lymph Nodes
from Patients with Minimal Disease. New therapies against
HIV-1 require assessment of their impact on viral loads in
lymphoid tissue. Sensitive tools are now available to quan-
tify HIV RNA in plasma, but lymphoid tissues contain the
major depots of virus (3–12, 18, 19). In this study, we em-
phasized in situ hybridization of lymph node sections to
detect both productively infected cells as well as immune
complexes of virus on FDCs. We found that viral infection
was active in the unenlarged lymph nodes of asymptomatic
patients with CD41 counts .500/ml.
The GCs of untreated patients contained p24 gag pro-
tein and HIV-1 RNA bound to FDCs. HIV trapping oc-
curred exclusively in the light zone where the FDC net-
work was activated and CD231. This part of the FDC
network can be missed or overrepresented in a GC, de-
pending upon the plane of sectioning. This needs to be
taken into account when amounts of captured RNA are
estimated. By measuring the FDC-bound HIV RNA in
GCs containing both light and dark zones, we found that
15–30% of the GCs in most lymph nodes was occupied by
RNA when the plasma viremia varied from 500–50,000
copies/ml.
Plasma HIV-1 RNA concentrations were much better
reflected by the number of actively infected cells in the
lymph nodes (Fig 2). In patients with plasma loads of ,500
copies/ml, only a few cells expressed HIV RNA and the
grain counts were low. With increasing plasma viremia, the
number of cells with HIV RNA per total area increased. In
patients with plasma viremia of .15,000 copies/ml, the
vast majority of hot cells had high grain counts, suggesting
high levels of viral replication in each.
It has been suggested that chronically infected macro-
phages, being more resistent to the cytopathic effect of HIV,
could be responsible for chronic virus production (28).
Therefore, we investigated the lineage of productively in-
fected cells by double labeling the lymph node sections for
HIV-1 RNA and the CD68 macrophage marker or the
CD4 T cell marker. Exclusively, CD41 lymphocytes of the
CD45RO1 memory type, and not larger CD681 mac-
rophages, produced HIV-1 RNA in the lymph nodes. It is
possible that b-chemokines (29, 30) decrease the replica-
tion of virus in macrophages in situ.
Morphology of HIV-1–infected Lymph Nodes from Patients
with High CD4 Counts and without Persistent Generalized
Lymphadenopathy.  In spite of the excellent clinical status
of our patients (Table 1), even the nonenlarged lymph
nodes showed alterations that are seen in viral lymphadeni-
Table 4. Patient Features before and after Triple Drug Therapy
Patient
No.
Bx
CD41 cell counts Plasma RNA values RNA1 cells in GC
RNA1 cells in ELT 
(mean)
Diffuse RNA:
percent of GC area
Baseline
At second
bx *Baseline
‡At second
bx Baseline
At second
bx Baseline
At second
bx Baseline
At second
bx
cells/ml copies/ml
1 540 490 300,000 ,20 33 0 22 0 42.0 7.2
2 580 570 49,000 630 63 2 31 2 37.1 2.9
3 510 720 15,000 645 28 15 22 17 16.7 28.5
4 560 600 10,000 ,20 11 0 4 0 31.0 1.4
5 1,320 1,110 6,500 113 0 0 5 0 17.2 1.5
6 560 1,000 6,000 45 4 0 8 0 8.3 4.7
7 570 720 ,500 ,20 3 0 10 0 14.7 7.6
8 1,080 1,170 ,500 ,20 No GCs No GCs 4 0 No GCs No GCs
9 380 540 48,000 ,20 19 0 12 0 27.6 0.7§
10 570 500 37,500 ,20 22 0 9 0 15.6 2.1i
11 560 680 31,000 ,20 37 0 14 0 23.0 3.4i
12 560 550 9,200 ,20 13 0 7 0 17.5 2.7i
*Conventional PCR.
‡Ultrasensitive PCR.
§One GC with 12.8%.
iThree or more GCs with 7–10.2%.957 Racz et al.
tis. For unenlarged nodes (group A patients), the follicles
were normal in size, whereas enlarged nodes (group B pa-
tients) had follicular hyperplasia. In both groups, the folli-
cles could be diffusely distributed rather than confined to
the outer cortex. The GC microenvironment was clearly
disturbed. For example, there were many infiltrating CD81
T cells, and the CD23 antigen was upregulated on the
FDC network. The FDC network was expanded in those
lymph nodes that had hyperplastic GCs, but no FDC dam-
age was detectable. This is in contrast to more advanced
stages of disease in which a deterioration of the FDC net-
work occurs consistently during the follicular hyperplasia
stage of PGL (for review see reference 31). 
It is thought that HIV-1 within the GC is somehow re-
sponsible for FDC death. However, the lack of FDC loss in
our patients despite the presence of HIV-1 RNA, p24 pro-
tein, and a substantial history of infection (1–6 yr), suggests
that HIV-1 infection per se does not damage the FDCs.
Possibly it is a loss of CD41 T cells that underlies FDC
malfunction, and CD41 T cells were preserved in the pa-
tients that we studied here. FDC development in mice
with severe combined immunodeficiency mice requires
transfer of both B and T cells (32).
In many ways, the histologic changes that were seen in
unenlarged lymph nodes were similar to those reported
earlier for more extensive disease including generalized
lymphadenopathy. The major difference was in the extent
of follicular hyperplasia, which was minimal in the unen-
larged lymph nodes. Since the follicles nevertheless har-
bored productively infected cells as well as FDC-bound
RNA and p24 of HIV-1, our observations suggest that host
factors rather than the virus itself or viral components de-
posited in the GC drive follicular hyperplasia. 
Response to Triple Drug Therapy. Viral burdens in both
plasma and lymph nodes were markedly sensitive to triple
drug therapy, with a major effect being within 28 d of treat-
ment. Most productively infected T cells in lymph nodes
had disappeared in 28 d and were undetectable by 3 mo. 
There were some unexpected findings that require fur-
ther study. The first relates to the FDC network of viral
RNA that was sensitive to therapy as described (12, 33).
The longevity of immune complexes on FDCs is substan-
tial with half lives in mice of .1–2 mo. Yet we found
marked decreases of viral RNA on FDCs in just 28 d (Fig.
4, a and b). It will be important to assess RNA on FDCs af-
ter longer periods of therapy. A second surprise was that
HIV-1 p24 protein was retained for longer periods, even in
follicles (Fig. 4, c and d) in which HIV-1 RNA was unde-
tectable after 3 mo of therapy. Because of a remarkable sta-
bility of the p24 core during the decay of HIV-1 (34), we
assume that in our patients the FDC-bound p24 antigen is
not virion associated. Third, there were clear differences in
the clearance of FDC-bound HIV RNA among GCs
within the same lymph node. If the lability of FDC-associ-
ated HIV RNA is determined by the equilibrium between
production and clearance of virus from the circulation as
suggested (12), the same magnitude of RNA decay in all
GCs was expected, since in all of our patients plasma viral
load was suppressed to undetectable levels. The apparent
variability in the viral reservoirs that we observed in differ-
ent GCs mandates some caution in monitoring the efficacy
of therapy with fine-needle aspiration, or with tissues con-
taining a limited number of GCs, e.g., tonsil and gut biop-
sies.
CD41 T Cell Proliferation with GCs of HIV-1–infected In-
dividuals.  Immune reconstitution is a vital aspect of ther-
apy, and suppression of virus replication can be accompa-
nied by increases in the number of circulating CD41 T
cells (1, 2, 24, 35–39). It has been suggested that the T cell
expansion is a reflection of cell proliferation (24, 36). In
contrast, Wolthers at al. (38) reported that cellular redistri-
bution rather than de novo production of CD41 T cells ac-
counts for the initial increase of memory T cells during
therapy. Our demonstration of high proliferation rates (la-
beling for the Ki-67 cell cycle antigen) in CD41 T cells in
lymph nodes compared with uninfected controls provides
direct evidence that an accelerated CD41 T cell turnover
does indeed occur in HIV-1 infection. The high prolifera-
tion rates occur in intrafollicular CD41/CD45RO1 lym-
phocytes (Fig. 3 b), whereas control GCs contain many
such lymphocytes but few in the cell cycle. Possibly the
proliferation of intrafollicular CD41 T cells at the baseline
and after treatment is driven by immune complexes of
HIV-1 p24 presented by FDCs or GC dendritic cells. In
mice, T cells in GCs do proliferate upon antigenic stimula-
tion (40). Our findings reveal a peripheral regenerative ca-
pacity within GCs, and this may account for observed in-
creases in CD41 T cell counts during triple drug therapy.
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